Platinum-Resistant Ovarian Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Platinum-Resistant Ovarian Cancer Emerging Therapy and TPP Insights

Thelansis’s “Platinum-Resistant Ovarian Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Platinum-Resistant Ovarian Cancer Overview

Platinum-resistant ovarian cancer refers to the recurrence of the disease within 6 months after initial platinum-based chemotherapy, and this definition now also encompasses patients progressing within 6 months after multiple rounds of chemotherapy. The time gap between the last platinum treatment and cancer relapse influences the choice of subsequent treatment, be it platinum-based or other chemotherapeutics in clinical practice. Patients who receive platinum chemotherapy are classified as platinum-sensitive or platinum-resistant based on their platinum-free interval, i.e., the duration from the end of treatment to relapse. Unfortunately, nearly all patients with high-grade serous ovarian cancer (HGSOC) eventually develop platinum resistance and succumb to the disease. The urgent need for effective and well-tolerated treatments for platinum-resistant ovarian cancer remains a significant challenge. Platinum-resistant ovarian cancer presents limited treatment options and carries a dismal prognosis.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
    • Pipeline analysis
    • Target patients for emerging therapies
    • Key companies
    • Key mechanism of actions
    • Launch date estimates, etc.
  • Clinical trial landscape analysis
    • Target patient segments
    • Trial endpoints
    • Trial design
    • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
    • Performance of key current therapies
    • Top areas of unmet needs
    • Opportunity sizing for key unmet needs
  • Target Product Profiles
    • Attributes and levels
    • Physician likelihood of prescribing
    • Expected patient shares
  • KOL insights on key emerging therapies
    • Level of awareness
    • Expected use / line of therapy
    • Extent to fulfil key unmet needs
    • KOL quotes


Read more: Platinum-Resistant Ovarian Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more